Miltenyi Biotec Sars-Cov-2 Antigen For Investigation of Virus-Specific Immune Responses; 25 µg

Miltenyi Biotec The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor. | The SARS-CoV-2 mutant strain B.1.617.2, also known as Delta variant, was first identified during the Covid-19 pandemic in India in late 2020. Due to increased transmissibility it spread rapidly around the globe. The B.1.617.2 lineage differs from the wild-type sequence by multiple amino acid mutations of which two key amino acid substitutions L452R and T478K occur in the RBD. The L452R mutation is suspected to confer increased affinity of the RBD to the ACE2 receptor and may decrease recognition of the B.1.617.2 lineage by the immune system. | The SARS-CoV-2 RBD B.1.617.2 (HEK) protein covers amino acids R319 to S591 of the spike protein and contains the L452R and T478K mutations, as well as a C-terminal His-tag and a N-terminal AviTag. Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the RBD. | | | - MLTY (Additional S&H or Hazmat Fees May Apply)